Replies to post #247461 on Biotech Values

[vinmantoo]

The core inhibitor is interesting in that it shows this mechanism could lead to lower hep surface antigen

Since the CEO of Aligos knows about ENTA from his positive comments about EDP-235 and that Covid data, maybe they should talk to ENTA about partnering their HepB drug which reduced Capsid antigen, with EDP-514. Maybe not partnering but running some pre-clinical trials or phase I trials using them together with a nuc.